NYSE · Healthcare · Statistics
Pfizer, Inc. valuation and key ratios.
Valuation, profitability, balance-sheet health, and risk metrics for PFE, refreshed each market session.
Section freshness
Price Aug 19, 1:15 PM EDT · Statements Jun 27, 8:00 PM EDT
Key metrics at a glance
The numbers most investors check first
Market cap
$160.50B
P/E (TTM)
37.05
Forward P/E
—
FCF yield
6.84%
Return on equity
5.09%
Dividend yield
6.31%
Valuation
- Market cap
- $160.50B
- Enterprise value
- $222.72B
- P/E (TTM)
- 37.05
- Price / book
- 1.88
- EPS (TTM)
- $0.76
Long-run compounding
CAGR since IPO and aggregate price growth.
Adjusted daily closes are annualized over the full price history; dividends are not included in this price-only return view.
- CAGR since IPO
- 5.03%
- From first adjusted close on August 21, 2006
- Aggregate CAGR
- 3.51%
- 1Y, 3Y, 5Y, 10Y blended CAGR
- First tracked close
- $10.56
- August 21, 2006
- History span
- 20 yrs
- Aug 21, 2006 to Aug 19, 2026 · 5,030 closes
- Latest tracked close
- $28.16
- August 19, 2026
- All-time high
- $61.71
- December 20, 2021
- All-time low
- $11.02
- March 2, 2009
- History source
- Long range
- Yahoo Finance
Valuation map
Risk and scale
Less volatile than the market
Pro formula stack
Ratios investors search for after the headline quote.
These are TECHi-computed from overview, income statement, balance sheet, and cash-flow rows when market-data sources expose the ingredients.
- FCF yield
- 6.84%
- TTM free cash flow / market cap
- FCF / share
- $1.93
- TTM free cash flow / shares outstanding
- Earnings yield
- 2.70%
- Inverse P/E
- CROIC
- 7.45%
- FCF / invested capital
- TECHi quality score
- 4 / 7
- 7-point profitability, cash, leverage, and trend check
Quality and capital returns
TTM FCF / TTM net income
Balance-sheet and reinvestment reads
Total debt / TTM FCF
Distress and optionality read
PFE Altman Z-score needs a fuller balance sheet.
TECHi computes a non-financial-company Altman-style score from working capital, retained earnings, EBIT, market value, liabilities, revenue, and assets. It is not a bankruptcy prediction, but it gives pro readers a fast stress screen that most quote pages do not show beside live valuation metrics.
- Net cash / share
- $-10.92
- Cash minus debt, per share
- Working capital
- $8.71B
- Current assets minus current liabilities
- Debt growth YoY
- +2.26%
- Latest quarter vs same quarter last year
Valuation read
PFE trades at 37.05× trailing earnings.
A trailing P/E above 30 means the market is paying up for PFE. That premium has to be earned with above-average revenue or earnings growth — pair this with the forward P/E (—) and the PEG ratio (—) before forming a view.
Profitability
- Net margin
- 4.72%
- Return on equity
- 5.09%
- Return on assets
- 2.15%
- Debt / equity
- 0.74
- Current ratio
- 1.27
- >1 = covers near-term liabilities
- Beta (5Y)
- 0.28
Margin profile
Profitability read
PFE converts 4.7% of revenue into net income.
Sub-8% net margins leave little cushion for input-cost shocks. Look for the operating-margin trend and the gross-margin floor — a stable gross with a recovering operating margin is the cleanest setup.
Per-share & range
- Dividend yield
- 6.31%
- Forward yield
- Shares outstanding
- 5.70B
- 52w high
- $28.75
- 52w low
- $23.58
Corporate actions
Stock split history
Adjusted for all historical splits
- Split events
- 0
Reported fundamentals
Company statistics fields
These figures come from the latest issuer filings and live quote-derived formulas.
- Book value
- $14.95
- TECHi unified data
- Earnings growth YoY
- -107.84%
- TECHi unified data
- 50-day average
- $25.00
- TECHi unified data
- 200-day average
- $25.16
- TECHi unified data
Frequently asked
Common questions.
What is Pfizer, Inc.'s market capitalization?
Pfizer, Inc. (PFE) currently shows a fresh market-cap field of $160.5 billion.
What is PFE's P/E ratio?
PFE's available trailing P/E field is 37.05.
Where do TECHi's PFE statistics come from?
The Statistics page uses TECHi's unified market-data layer and omits fields whose winning source is missing or explicitly stale.